CN111479825A - 特异性结合分子 - Google Patents

特异性结合分子 Download PDF

Info

Publication number
CN111479825A
CN111479825A CN201880062689.7A CN201880062689A CN111479825A CN 111479825 A CN111479825 A CN 111479825A CN 201880062689 A CN201880062689 A CN 201880062689A CN 111479825 A CN111479825 A CN 111479825A
Authority
CN
China
Prior art keywords
ser
thr
vnar
gly
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880062689.7A
Other languages
English (en)
Chinese (zh)
Inventor
O·乌巴
C·巴雷勒
A·波特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ellis Morgan
Original Assignee
Ellis Morgan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ellis Morgan filed Critical Ellis Morgan
Publication of CN111479825A publication Critical patent/CN111479825A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201880062689.7A 2017-09-27 2018-09-27 特异性结合分子 Pending CN111479825A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762563948P 2017-09-27 2017-09-27
US62/563,948 2017-09-27
US201862667126P 2018-05-04 2018-05-04
US62/667,126 2018-05-04
PCT/EP2018/076333 WO2019063726A1 (en) 2017-09-27 2018-09-27 SPECIFIC BINDING MOLECULES

Publications (1)

Publication Number Publication Date
CN111479825A true CN111479825A (zh) 2020-07-31

Family

ID=63720686

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880062689.7A Pending CN111479825A (zh) 2017-09-27 2018-09-27 特异性结合分子

Country Status (7)

Country Link
US (2) US11919949B2 (https=)
EP (2) EP3688030B1 (https=)
JP (3) JP2020535811A (https=)
KR (1) KR102657978B1 (https=)
CN (1) CN111479825A (https=)
CA (1) CA3075367A1 (https=)
WO (1) WO2019063726A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109477084A (zh) * 2016-07-19 2019-03-15 国立研究开发法人农业·食品产业技术综合研究机构 使用等离子体在植物细胞内导入物质的方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021028837A1 (en) * 2019-08-13 2021-02-18 Waters Technologies Corporation Affinity resins and sample preparation devices based on cartilaginous fish ignar derived binding domains
GB202020152D0 (en) * 2020-12-18 2021-02-03 Elasmogen Ltd Fast-track humanisation of specific binding molecules
CN118475603A (zh) * 2021-11-03 2024-08-09 香港城市大学深圳研究院 高亲和力抗EGFP和抗SARS-CoV-2 vNAR单域抗体及其用途
GB202407865D0 (en) 2024-06-03 2024-07-17 Elasmogen Ltd Self immolative compounds

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105531370A (zh) * 2013-04-23 2016-04-27 阿伯丁大学理事会 治疗靶向特异性vnar结构域与icosl的分离
US20160137726A1 (en) * 2012-05-07 2016-05-19 The University Court Of The University Of Aberdeen Single domain binding molecule

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
PT1419179E (pt) 2001-08-10 2010-03-16 Univ Aberdeen Domínios de ligação de antigenes
JP2008511286A (ja) 2004-06-02 2008-04-17 ダイアテック・ピーティワイ・リミテッド サメ類のＩｇＮＡＲドメインに基づく結合成分
WO2011056056A2 (es) 2009-11-04 2011-05-12 Laboratorios Silanes, S.A. De C.V. Dominios vhnar anti -citocinas
PE20141522A1 (es) * 2011-08-17 2014-11-17 Glaxo Group Ltd Proteinas y peptidos modificados
EP3160995A2 (en) 2014-06-26 2017-05-03 Ossianix Inc. Semi-synthetic nurse shark vnar libraries for making and using selective binding compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160137726A1 (en) * 2012-05-07 2016-05-19 The University Court Of The University Of Aberdeen Single domain binding molecule
CN105531370A (zh) * 2013-04-23 2016-04-27 阿伯丁大学理事会 治疗靶向特异性vnar结构域与icosl的分离

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MARINA KOVALEVA ET AL.: "Shark variable new antigen receptor biologics – anovel technology platform for therapeutic drugdevelopment" *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109477084A (zh) * 2016-07-19 2019-03-15 国立研究开发法人农业·食品产业技术综合研究机构 使用等离子体在植物细胞内导入物质的方法

Also Published As

Publication number Publication date
JP2025160405A (ja) 2025-10-22
JP7818828B2 (ja) 2026-02-24
US20240247058A1 (en) 2024-07-25
JP2023175822A (ja) 2023-12-12
US11919949B2 (en) 2024-03-05
EP3688030A1 (en) 2020-08-05
KR20200062215A (ko) 2020-06-03
WO2019063726A1 (en) 2019-04-04
CA3075367A1 (en) 2019-04-04
EP4570826A3 (en) 2025-09-24
US12371484B2 (en) 2025-07-29
US20200407437A1 (en) 2020-12-31
JP2020535811A (ja) 2020-12-10
KR102657978B1 (ko) 2024-04-16
EP4570826A2 (en) 2025-06-18
EP3688030B1 (en) 2024-12-11

Similar Documents

Publication Publication Date Title
US9212231B2 (en) TRAIL R2-specific multimeric scaffolds
CN107001485B (zh) 蛋白质异二聚体及其用途
US12371484B2 (en) Specific binding molecules
TWI688572B (zh) 包含dr5-結合結構域的多價分子
DK2814842T3 (en) ANTIBODIES BINDING PEPTIDOGLYCAN RECOGNITION PROTEIN 1
KR102649757B1 (ko) 5t4 및 4-1bb에 결합하는 항원 결합 단백질 및 관련 조성물 및 방법
WO2013003647A2 (en) Multispecific stacked variable domain binding proteins
KR20150139531A (ko) 이중특이적 이가 scFv-Ｆｃ 분자
TR201808591T4 (tr) Bir evrensel bir antikor iskeleti kullanılarak tavşan antikorların insanlaştırılması.
CN109641037A (zh) 抗psma抗体及其用途
TW201010725A (en) Anti-IL-12/IL-23 antibodies
CN109705218A (zh) Asgpr抗体及其用途
US20210246217A1 (en) Trimeric polypeptide complexes and uses thereof
KR20230163485A (ko) 면역 이펙터 세포 재유도를 위한 물질 및 방법
JP2015164940A (ja) 遺伝子操作されたウサギ抗体可変ドメイン及びその使用
US12460010B2 (en) Antibodies that bind TNFRSF25
CA3190463A1 (en) Il27r.alpha. binding molecules and methods of use
US20250346659A1 (en) Specific binding molecules
KR20240004694A (ko) 항체
CN117843776B (zh) 抗体分子、核酸、制药用途及炎性疾病治疗方法
RU2804458C2 (ru) Антигенсвязывающие белки, связывающиеся с 5t4 и 4-1bb, и относящиеся к ним композиции и способы
RU2859397C2 (ru) МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕ IL27Rα, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
HK40041672B (zh) 新型抗cd39抗体

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination